Name: Irbesartan-[d7]
Brand: BOC Sciences
Rating: 5 (1 reviews)

General Information

Catalog: BLP-005843

CAS: 1329496-43-6

Molecular Formula: C27H22D7F3N6O3

Molecular Weight: 435.57

Chemical Structure

Description	Irbesartan-[d7] is an isotopically labelled analogue of Irbesartan. Irbesartan is an antagonist of the angiotensin II type 1 (AT1) receptor. It is an insurmountable antagonist of AT1, as its antagonism cannot be overcome by increasing concentrations of angiotensin II.
Synonyms	2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one-d7; Irbesartan D7; BMS-186295-d7; SR-47436-d7
IUPAC Name	2-(2,2,3,3,4,4,4-heptadeuteriobutyl)-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
Related CAS	138402-11-6 (unlabelled)
Isomeric SMILES	[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])CC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
Canonical SMILES	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5
InChI	InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)/i1D3,2D2,3D2
InChI Key	YOSHYTLCDANDAN-NCKGIQLSSA-N
Purity	98% by CP

Irbesartan-[d7], a deuterated variant of the angiotensin II receptor blocker irbesartan, plays a pivotal role in pharmaceutical and clinical research. Delve into the applications of Irbesartan-[d7] with a high degree of perplexity and burstiness:

Pharmacokinetic Studies: Positioned at the heart of pharmacokinetic inquiries, Irbesartan-[d7] provides invaluable insights into the absorption, distribution, metabolism, and excretion dynamics of irbesartan. The deuterium labeling introduces a stable isotope crucial for meticulously tracking the molecule within biological systems. This data is paramount for optimizing dosage regimens and unraveling the intricate nuances of the drug's bioavailability.

Bioanalytical Research: Within the realm of bioanalysis, Irbesartan-[d7] assumes a critical role as an internal standard for quantifying irbesartan levels in biological specimens. Its incorporation ensures precision and reliability in mass spectrometry analyses, facilitating investigations into drug-drug interactions and therapeutic concentration monitoring. This function holds profound significance in the realm of clinical trials and initiatives focusing on therapeutic drug monitoring.

Metabolism Studies: Researchers harness Irbesartan-[d7] in metabolism explorations to dissect the complex pathways through which irbesartan undergoes metabolic alterations. The distinctive mass differentiation enables scientists to distinguish between the parent drug and its metabolites, shedding light on how the body metabolizes the medication. This knowledge serves as the cornerstone for devising safer and more efficacious therapeutic interventions.

Drug Interaction Investigations: In the exploration of potential interactions involving irbesartan, particularly in conjunction with medications metabolized through analogous pathways, the utility of Irbesartan-[d7] shines brightly. Understanding these interactions is imperative for preempting adverse effects and enhancing patient safety in scenarios involving multiple medications.